The problem
A conclusion can outlive the evidence trail that justified it.
Trial Provenance · Partner distribution
Diligence and research partners
Licensing teams, investors, research services and scientific diligence firms
The offer
Deliver the conclusion with a claim-to-source ledger, manifests and explicit UNKNOWN/conflict states.
Good fit
Best for repeatable public-evidence review across one trial or a portfolio.
Boundary
Not investment advice and not a substitute for expert scientific judgment.
Possible commercial structures
Referral · Bundled delivery · Institutional relationship. Every arrangement requires case-by-case review and written approval; no public page creates compensation rights.
Potential partner classes: CROs · Trial infrastructure vendors · Licensing and diligence firms · Biotech consultants · Clinical-development advisors · Legal and regulatory advisors · Investor research services · Patient-advocacy research groups · Academic or nonprofit research services · Enterprise information providers